TMS Clinical and Research Service, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Los Angeles, CA 90024, United States..
TMS Clinical and Research Service, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Los Angeles, CA 90024, United States.
J Affect Disord. 2020 Dec 1;277:964-969. doi: 10.1016/j.jad.2020.09.011. Epub 2020 Sep 8.
Repetitive Transcranial Magnetic Stimulation (rTMS) is an effective intervention for treatment-resistant Major Depressive Disorder (MDD). Early improvement during high-frequency left-sided (HFL) stimulation of the dorsolateral prefrontal cortex (DLPFC) is an important predictor of longer-term outcome, but most patients benefit later in their treatment course. We examined patients without early improvement with HFL to determine whether augmentation with additional stimulation approaches improved treatment outcome.
139 participants received HFL in a measurement-based care paradigm. Participants who achieved < 20% improvement by treatment 10 could continue with HFL (N = 17) or receive one of two augmentation strategies: bilateral stimulation (BL; HFL followed by low-frequency stimulation of right DLPFC) (N = 69) or intermittent theta-burst priming of left DLPFC (iTBS-P) (N = 17) for their remaining treatment sessions. The primary outcome was the percent reduction in depressive symptoms at treatment 30.
Participants who achieved < 20% improvement by treatment 10 and continued with HFL showed limited benefit. iTBS-P participants had significantly greater improvement, while those receiving BL trended toward improved outcomes. Ten sessions of either augmentation strategy appeared necessary to determine the likelihood of benefit.
Augmentation of early non-response to HFL appears to improve rTMS outcomes, with a novel iTBS-P strategy surpassing both continued HFL or BL treatment in participants with < 20% improvement after 10 treatments. These findings suggest that measurement-based care with addition of augmented stimulation for those not showing early improvement may yield superior rTMS treatment outcomes.
重复经颅磁刺激(rTMS)是治疗难治性重度抑郁症(MDD)的有效干预手段。高频左侧(HFL)刺激背外侧前额叶皮质(DLPFC)后早期改善是长期疗效的重要预测因素,但大多数患者在治疗过程中晚期才受益。我们对 HFL 治疗早期无改善的患者进行检查,以确定是否通过额外的刺激方法来改善治疗结果。
139 名参与者在基于测量的护理范式中接受 HFL。在第 10 次治疗时达到<20%改善的参与者可以继续接受 HFL(N=17)或接受两种增强策略之一:双侧刺激(BL;HFL 后右侧 DLPFC 低频刺激)(N=69)或左侧 DLPFC 间歇性 theta 爆发刺激(iTBS-P)(N=17)进行剩余的治疗。主要结局是治疗第 30 天抑郁症状的减少百分比。
在第 10 次治疗时达到<20%改善并继续接受 HFL 的参与者获益有限。接受 iTBS-P 的参与者改善程度显著更大,而接受 BL 的参与者则倾向于改善结果。两种增强策略中的任何一种的 10 个疗程似乎都有必要确定获益的可能性。
增强对 HFL 早期无反应的效果似乎可以改善 rTMS 的结果,与继续接受 HFL 或 BL 治疗相比,对于在 10 次治疗后改善<20%的参与者,新型 iTBS-P 策略具有更好的效果。这些发现表明,对于那些早期没有改善的患者,采用基于测量的护理并增加增强刺激可能会产生更好的 rTMS 治疗结果。